Alamar Biosciences, in collaboration with the Alzheimer's Disease Data Initiative and Gates Ventures, launched a large-scale plasma proteomic profiling project targeting Alzheimer's disease and related dementias. Utilizing the ultra-sensitive NULISA platform, the consortium aims to generate one of the largest clinically annotated proteomic datasets globally. This initiative supports biomarker discovery, progression tracking, and therapeutic development across diverse international cohorts with open data sharing to accelerate research impact.